These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 17239261)
21. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881 [TBL] [Abstract][Full Text] [Related]
22. Predicting the recurrence/metastasis of stage I and II breast cancer without lymph node metastasis. Mukai M; Sato S; Kimura T; Komatsu N; Ninomiya H; Nakasaki H; Ogoshi K; Makuuchi H Oncol Rep; 2004 Oct; 12(4):745-8. PubMed ID: 15375494 [TBL] [Abstract][Full Text] [Related]
23. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Anders CK; Hsu DS; Broadwater G; Acharya CR; Foekens JA; Zhang Y; Wang Y; Marcom PK; Marks JR; Febbo PG; Nevins JR; Potti A; Blackwell KL J Clin Oncol; 2008 Jul; 26(20):3324-30. PubMed ID: 18612148 [TBL] [Abstract][Full Text] [Related]
24. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Sanpaolo P; Barbieri V; Genovesi D Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742 [TBL] [Abstract][Full Text] [Related]
25. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer. Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862 [TBL] [Abstract][Full Text] [Related]
26. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy. Meyer A; Dörk T; Sohn C; Karstens JH; Bremer M Radiother Oncol; 2007 Mar; 82(3):349-53. PubMed ID: 17250914 [TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Barrier A; Boelle PY; Lemoine A; Tse C; Brault D; Chiappini F; Lacaine F; Houry S; Huguier M; Flahault A; Dudoit S Dis Colon Rectum; 2005 Dec; 48(12):2238-48. PubMed ID: 16228831 [TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944 [TBL] [Abstract][Full Text] [Related]
29. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Albain KS; Paik S; van't Veer L Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534 [TBL] [Abstract][Full Text] [Related]
30. Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Lee SC; Xu X; Chng WJ; Watson M; Lim YW; Wong CI; Iau P; Sukri N; Lim SE; Yap HL; Buhari SA; Tan P; Guo J; Chuah B; McLeod HL; Goh BC Pharmacogenet Genomics; 2009 Nov; 19(11):833-42. PubMed ID: 19809382 [TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Pawitan Y; Bjöhle J; Amler L; Borg AL; Egyhazi S; Hall P; Han X; Holmberg L; Huang F; Klaar S; Liu ET; Miller L; Nordgren H; Ploner A; Sandelin K; Shaw PM; Smeds J; Skoog L; Wedrén S; Bergh J Breast Cancer Res; 2005; 7(6):R953-64. PubMed ID: 16280042 [TBL] [Abstract][Full Text] [Related]
33. Stable Gene Signature Selection for Prediction of Breast Cancer Recurrence Using Joint Mutual Information. Sehhati M; Mehridehnavi A; Rabbani H; Pourhossein M IEEE/ACM Trans Comput Biol Bioinform; 2015; 12(6):1440-8. PubMed ID: 26671813 [TBL] [Abstract][Full Text] [Related]
34. Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer. Kuderer NM; Lyman GH Cancer Invest; 2009 Nov; 27(9):885-90. PubMed ID: 19832034 [No Abstract] [Full Text] [Related]
35. Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. Nuyten DS; Hastie T; Chi JT; Chang HY; van de Vijver MJ Eur J Cancer; 2008 Oct; 44(15):2319-29. PubMed ID: 18715778 [TBL] [Abstract][Full Text] [Related]
36. MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. Bedard PL; Mook S; Piccart-Gebhart MJ; Rutgers ET; Van't Veer LJ; Cardoso F Expert Opin Med Diagn; 2009 Mar; 3(2):193-205. PubMed ID: 23485165 [TBL] [Abstract][Full Text] [Related]
37. Likelihood ratios, sensitivity, and specificity values can be back-calculated when the odds ratios are known. Simel DL; Easter J; Tomlinson G J Clin Epidemiol; 2013 Apr; 66(4):458-60. PubMed ID: 23021858 [TBL] [Abstract][Full Text] [Related]
38. Comparison of prognostic gene expression signatures for breast cancer. Haibe-Kains B; Desmedt C; Piette F; Buyse M; Cardoso F; Van't Veer L; Piccart M; Bontempi G; Sotiriou C BMC Genomics; 2008 Aug; 9():394. PubMed ID: 18717985 [TBL] [Abstract][Full Text] [Related]
39. Systematic review: gene expression profiling assays in early-stage breast cancer. Marchionni L; Wilson RF; Wolff AC; Marinopoulos S; Parmigiani G; Bass EB; Goodman SN Ann Intern Med; 2008 Mar; 148(5):358-69. PubMed ID: 18252678 [TBL] [Abstract][Full Text] [Related]
40. Number needed to misdiagnose: a measure of diagnostic test effectiveness. Habibzadeh F; Yadollahie M Epidemiology; 2013 Jan; 24(1):170. PubMed ID: 23232619 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]